DE69822164D1 - Verfahren zur identifizierung von verbindungen mit verminderter systemischer aktivität - Google Patents

Verfahren zur identifizierung von verbindungen mit verminderter systemischer aktivität

Info

Publication number
DE69822164D1
DE69822164D1 DE69822164T DE69822164T DE69822164D1 DE 69822164 D1 DE69822164 D1 DE 69822164D1 DE 69822164 T DE69822164 T DE 69822164T DE 69822164 T DE69822164 T DE 69822164T DE 69822164 D1 DE69822164 D1 DE 69822164D1
Authority
DE
Germany
Prior art keywords
reduced systemic
human
systemic activity
identifying connections
compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69822164T
Other languages
English (en)
Other versions
DE69822164T2 (de
Inventor
Keith Biggadike
Martyn Angell
Alexandrou Procopiou
Rosanne Mary Farrell
Usha V Ramesh
Duncan Stuart Holmes
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Glaxo Group Ltd
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9713819.2A external-priority patent/GB9713819D0/en
Priority claimed from GBGB9713818.4A external-priority patent/GB9713818D0/en
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of DE69822164D1 publication Critical patent/DE69822164D1/de
Application granted granted Critical
Publication of DE69822164T2 publication Critical patent/DE69822164T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J31/00Normal steroids containing one or more sulfur atoms not belonging to a hetero ring
    • C07J31/006Normal steroids containing one or more sulfur atoms not belonging to a hetero ring not covered by C07J31/003
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/38Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/44Glucocorticosteroids; Drugs increasing or potentiating the activity of glucocorticosteroids
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J17/00Normal steroids containing carbon, hydrogen, halogen or oxygen, having an oxygen-containing hetero ring not condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J3/00Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by one carbon atom
    • C07J3/005Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by one carbon atom the carbon atom being part of a carboxylic function
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J33/00Normal steroids having a sulfur-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C07J33/005Normal steroids having a sulfur-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton spiro-condensed
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J71/00Steroids in which the cyclopenta(a)hydrophenanthrene skeleton is condensed with a heterocyclic ring
    • C07J71/0005Oxygen-containing hetero ring
    • C07J71/0026Oxygen-containing hetero ring cyclic ketals
    • C07J71/0031Oxygen-containing hetero ring cyclic ketals at positions 16, 17
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/34Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
    • C12Q1/44Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase involving esterase
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90Enzymes; Proenzymes
    • G01N2333/914Hydrolases (3)
    • G01N2333/916Hydrolases (3) acting on ester bonds (3.1), e.g. phosphatases (3.1.3), phospholipases C or phospholipases D (3.1.4)
    • G01N2333/918Carboxylic ester hydrolases (3.1.1)
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00Screening for compounds of potential therapeutic value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pulmonology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Wood Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Pain & Pain Management (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Furan Compounds (AREA)
  • Steroid Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
DE69822164T 1997-06-30 1998-06-26 Verfahren zur identifizierung von verbindungen mit verminderter systemischer aktivität Expired - Fee Related DE69822164T2 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB9713818 1997-06-30
GBGB9713819.2A GB9713819D0 (en) 1997-06-30 1997-06-30 Method of reducing the systemic effects of compounds
GBGB9713818.4A GB9713818D0 (en) 1997-06-30 1997-06-30 Compounds
GB9713819 1997-06-30
PCT/EP1998/003905 WO1999001467A2 (en) 1997-06-30 1998-06-26 Therapeutically active compounds with low systemic activity due to reduce half life

Publications (2)

Publication Number Publication Date
DE69822164D1 true DE69822164D1 (de) 2004-04-08
DE69822164T2 DE69822164T2 (de) 2005-04-14

Family

ID=26311812

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69822164T Expired - Fee Related DE69822164T2 (de) 1997-06-30 1998-06-26 Verfahren zur identifizierung von verbindungen mit verminderter systemischer aktivität

Country Status (7)

Country Link
EP (1) EP0998484B1 (de)
JP (2) JP2000513380A (de)
AT (1) ATE260931T1 (de)
AU (1) AU8439998A (de)
DE (1) DE69822164T2 (de)
ES (1) ES2215310T3 (de)
WO (1) WO1999001467A2 (de)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0019172D0 (en) 2000-08-05 2000-09-27 Glaxo Group Ltd Novel compounds
US6750210B2 (en) 2000-08-05 2004-06-15 Smithkline Beecham Corporation Formulation containing novel anti-inflammatory androstane derivative
US6858596B2 (en) 2000-08-05 2005-02-22 Smithkline Beecham Corporation Formulation containing anti-inflammatory androstane derivative
US6787532B2 (en) 2000-08-05 2004-09-07 Smithkline Beecham Corporation Formulation containing anti-inflammatory androstane derivatives
US6759398B2 (en) 2000-08-05 2004-07-06 Smithkline Beecham Corporation Anti-inflammatory androstane derivative
US6777400B2 (en) 2000-08-05 2004-08-17 Smithkline Beecham Corporation Anti-inflammatory androstane derivative compositions
US6858593B2 (en) 2000-08-05 2005-02-22 Smithkline Beecham Corporation Anti-inflammatory androstane derivative compositions
US6777399B2 (en) 2000-08-05 2004-08-17 Smithkline Beecham Corporation Anti-inflammatory androstane derivative compositions
US6403580B1 (en) 2000-08-26 2002-06-11 Boehringer Ingelheim Pharma Kg Quinazolines, pharmaceutical compositions containing these compounds, their use and processes for preparing them
US6656946B2 (en) 2000-08-26 2003-12-02 Boehringer Ingelheim Pharma Kg Aminoquinazolines which inhibit signal transduction mediated by tyrosine kinases
US6617329B2 (en) 2000-08-26 2003-09-09 Boehringer Ingelheim Pharma Kg Aminoquinazolines and their use as medicaments
UA77656C2 (en) 2001-04-07 2007-01-15 Glaxo Group Ltd S-fluoromethyl ester of 6-alpha, 9-alpha-difluoro-17-alpha-[(2-furanylcarbonyl)oxy]-11-beta-hydroxy-16- alpha-methyl-3-oxoandrosta-1,4-dien-17-beta-carbothioacid as anti-inflammatory agent
GB2389530B (en) 2002-06-14 2007-01-10 Cipla Ltd Pharmaceutical compositions
US7456189B2 (en) 2003-09-30 2008-11-25 Boehringer Ingelheim International Gmbh Bicyclic heterocycles, medicaments containing these compounds, their use and processes for their preparation
AR059216A1 (es) 2006-01-27 2008-03-19 Sun Pharmaceutical Ind Ltd 11b-hidroxiandrosta-4-eno-3-onas
EP1921070A1 (de) 2006-11-10 2008-05-14 Boehringer Ingelheim Pharma GmbH & Co. KG Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstelllung
EA200901041A1 (ru) 2007-02-06 2010-02-26 Бёрингер Ингельхайм Интернациональ Гмбх Бициклические гетероциклы, содержащие эти соединения лекарственные средства, их применение и способ их получения
MX2010008621A (es) 2008-02-07 2010-09-24 Boehringer Ingelheim Int Heterociclos espirociclicos, medicamentos que contienen a estos compuestos, su uso y procedimiento para su preparacion.
CA2733153C (en) 2008-08-08 2016-11-08 Boehringer Ingelheim International Gmbh Cyclohexyloxy substituted heterocycles, pharmaceutical compositions containing these compounds and processes for preparing them
CN111201222A (zh) * 2017-10-11 2020-05-26 大金工业株式会社 具有不饱和基团的环状碳酸酯的制造方法和新型环状碳酸酯

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4093721A (en) * 1974-08-30 1978-06-06 Glaxo Laboratories Limited Pharmaceutical compositions of 6α,9α-difluoro-androst-4-ene-17β-carboxylates and derivatives thereof
SE449106B (sv) * 1980-07-10 1987-04-06 Otsuka Pharma Co Ltd Steroid med anti-inflammatorisk verkan samt komposition innehallande denna
DE3133631A1 (de) * 1981-08-21 1983-03-03 Schering Ag, 1000 Berlin Und 4619 Bergkamen Neue kortikoide ihre herstellung und verwendung
US4906661A (en) * 1981-11-12 1990-03-06 E. I. Du Pont De Nemours And Company Esters of aryloxypropanolamine derivatives
US4935421A (en) * 1981-11-12 1990-06-19 E. I. Du Pont De Nemours And Company 2-hydroxypropylamine aryl ester derivatives and pharmaceutical use
EP0174956B1 (de) * 1984-03-14 1990-08-16 BODOR, Nicholas S. Sanfte beta-adrenergische blockierende agenzien
IL78144A0 (en) * 1985-04-04 1986-07-31 Draco Ab Novel androstane-17beta-carboxylic acid esters
JP3176075B2 (ja) * 1991-03-04 2001-06-11 帝國製薬株式会社 新規なステロイド誘導体
JPH08502278A (ja) * 1992-10-16 1996-03-12 ビイク ネダーラント ベスローテン フェンノートシャップ 置換されたエタノールアミンエステル
US5629193A (en) * 1994-07-05 1997-05-13 Human Genome Sciences, Inc. Paraoxonase
US5775329A (en) * 1995-06-07 1998-07-07 Gensia, Inc. Method and compounds for diagnosing coronary artery disease
US6013244A (en) * 1995-12-29 2000-01-11 Glaxo Wellcome Inc. 21-(2-oxo-tetrahydrofuran)-thio pregnane derivatives, a process for their production and pharmaceutical compositions containing them
DE69609870T2 (de) * 1995-12-29 2001-01-25 Glaxo Group Ltd., Greenford 17beta-(2-oxo-tetrahydrofuran-4-yl)-thio-androstane derivate (17beta-(gamma-buttersäure-lacton)-thio derivate) zur behandlung von entzündungen, pharmazeutische präparate davon und ein verfahren zu ihrer herstellung
KR19990076859A (ko) * 1995-12-29 1999-10-25 그레이엄 브레레톤, 레슬리 에드워즈 17.베타.-카르복시, 카르보티오 및 아미드 안드로스탄 유도체의락톤 유도체

Also Published As

Publication number Publication date
ES2215310T3 (es) 2004-10-01
EP0998484A1 (de) 2000-05-10
JP2002322168A (ja) 2002-11-08
WO1999001467A2 (en) 1999-01-14
AU8439998A (en) 1999-01-25
JP2000513380A (ja) 2000-10-10
WO1999001467A3 (en) 1999-05-14
EP0998484B1 (de) 2004-03-03
ATE260931T1 (de) 2004-03-15
DE69822164T2 (de) 2005-04-14

Similar Documents

Publication Publication Date Title
DE69822164D1 (de) Verfahren zur identifizierung von verbindungen mit verminderter systemischer aktivität
ATE442851T1 (de) 1-deoxy-galactonojirimycin-derivate zur vewendung bei der behandlung von lysosomalen speicherkrankheiten mittels steigerung der lysosomalen alpha galactosidase a
AU3065989A (en) Polypeptide compounds having growth hormone releasing activity
DE3583008D1 (de) Pharmazeutische zusammensetzungen von dihydrocodeine/ibuprofen und verfahren.
ATE171625T1 (de) Therapeutische verwendung von actin-bindenden verbindungen
ATE77056T1 (de) Antikoerperkomplexe von haptenmodifizierten diagnostischen oder therapeutischen mitteln.
ATE113607T1 (de) Polypeptidverbindungen mit wachstumshormonfreisetzender aktivität.
DE68901140D1 (de) Waessrige loesung von fettloeslichen wirkstoffen.
DE3650358D1 (de) Diphosphonate enthaltende pharmazeutische Zusammensetzungen zur Behandlung von Arthrosis.
NO862096L (no) Fremgangsmaate for fremstilling av farmasoeytiske preparater inneholdende vevsplasminogenaktivator.
DE3769707D1 (de) Therapeutisches system mit geregelter wirkstoffabgabe.
DE3682229D1 (de) Zur stimulierung der traenensekretion verwendbare pharmazeutische praeparate.
SE8303003L (sv) Medel for att oka antitumorverkan hos antitumormedel
DK403384A (da) Enteralt effektivt, biologisk aktivt peptid- eller proteinmiddel ogfremgangsmaader til fremstilling deraf
ATE449847T1 (de) Hepatitis c rezeptorprotein cd81
NO863373D0 (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive aminosyre derivater.
DK325289A (da) Strontiumsalt, fremgangsmaade til fremstilling heraf samt farmaceutiske midler indeholdende saltet
DE3852625D1 (de) Vektoren und Verbindungen zur Expression von Zymogen-Formen von menschlichem Protein C.
EA199901061A1 (ru) Новые соли врс-пептидов с органопротективной активностью, способ их получения и их использование в терапии
DE3581650D1 (de) Derivat von p-aminophenol mit mucrosekretolytischer fluessiger und antipyretischer wirksamkeit, dessen verfahren zur herstellung und dessen pharmazeutische zusammensetzungen.
DK0487594T3 (da) Reagens til detektion af fibrinolytisk aktivitet
PT96045A (pt) Sistema transcutaneo aperfeicoado para aplicacao de compostos farmacologicamente activos em condicoes de ph controlado
ATE128358T1 (de) Therapeutische mittel für diabetisches gangrän.
PT87077A (pt) Terc-butylamino-3-(phenyl-2:-phenoxy)-1-propanol-2 and its acid addition salts for use as an active therapeutic substance
DE69430807D1 (de) Verfahren zur behandlung von lebererkrankungen und ähnlichen indikationen mit vasodilatierenden wirkstoffen

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee